Victoza for Fatty Liver: Evidence, Eligibility, Coverage
Victoza is not FDA approved for fatty liver disease (MASH). It is approved for type 2 diabetes and heart risk.
- For fatty liver disease (MASH)
- Not an approved use
- Active ingredient
- liraglutide
- How it is taken
- daily injection
Victoza: a quick look
About 13 hours is the half-life. Half is gone after 13 h, while five half-lives (2.7 d) leave about 3%.
In the 52-week LEAD-3 trial of type 2 diabetes, people lost 2.5 kg compared with 1.1 kg on placebo.
Sources: FDA label (DailyMed).
Who qualifies?
| Source | Who qualifies |
|---|---|
| FDA label | With diet and exercise, this medicine lowers blood sugar in adults and in children aged 10 and older with type 2 diabetes. |
| FDA label | Among adults with both type 2 diabetes and heart disease, it lowers the risk of heart attack, stroke, or heart-related death. |
Sources: FDA label (DailyMed).
For fatty liver, what changes?
| What changes | What the label says |
|---|---|
| Acute Pancreatitis | Can cause inflammation of the pancreas. Stop taking it and get care if severe stomach pain continues and sometimes spreads to the back. |
| Acute Gallbladder Disease | Gallstones and gallbladder inflammation can happen. Report pain in the upper right area of your belly, fever, or yellow skin or eyes. |
The source of these points is the FDA labels: FDA DailyMed.
The label lists these warnings: FDA DailyMed label.
Coverage for fatty liver
Part D plans may provide coverage for a GLP-1 for fatty liver disease, for moderate to severe sleep apnea, or for type 2 diabetes.
The source listed here: medicare.gov.
- Victoza Cost
- Victoza Coupon and Savings Card
- Victoza Cost Without Insurance
- Victoza Cost With Insurance
- Does Medicare Cover Victoza? Criteria, Copay, How to Appeal
- Cheapest Way to Get Victoza
- Is Victoza Covered by Insurance? Criteria, Copay, Appeal
- Does Medicaid Cover Victoza? Criteria, Copay, How to Appeal
Other fatty liver options
| Medicine | For fatty liver disease (MASH) | How it is taken | Trial result |
|---|---|---|---|
 Wegovy | FDA approved | weekly injection or daily tablet | 62.9% mASH resolved without worse scarring |
| Victoza | Not an approved use | daily injection | Not listed |
 Ozempic | Not an approved use | weekly injection | Not listed |
 Rybelsus | Not an approved use | daily tablet | Not listed |
 Mounjaro | Not an approved use | weekly injection | Not listed |
 Zepbound | Not an approved use | weekly injection | Not listed |
 Foundayo | Not an approved use | daily tablet | Not listed |
 Trulicity | Not an approved use | weekly injection | Not listed |
 Saxenda | Not an approved use | daily injection | Not listed |
| Byetta | Not an approved use | twice-daily injection | Not listed |
Sources listed: FDA DailyMed label, PubMed.
Ask your prescriber these questions
- Does the label cover the stage of scarring in my liver?
- How will we check if the liver is improving?
Please read the entire Victoza prescribing information on DailyMed.